Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 2Renal Insufficiency, Chronic 1Renal Insufficiency 1Kidney Failure, Chronic 1Hematologic Neoplasms 1

Interventions

pembrolizumab 69Nivolumab 69cabozantinib 45Ipilimumab 38Specimen Handling 33Magnetic Resonance Spectroscopy 33lenvatinib 26Axitinib 25belzutifan 21Sunitinib 18Biopsy 15Radiosurgery 14CTLA-4 Antigen 13atezolizumab 12Everolimus 10pazopanib 8fludarabine 8avelumab 8Bevacizumab 8toripalimab 7cemiplimab 7Nephrectomy 7Immunoglobulin G 7Cyclophosphamide 7aldesleukin 6Standard of Care 6Radiotherapy 6Blood Specimen Collection 6spartalizumab 5palbociclib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Kidney Transplantation × 1 year × Clear all
NCT05725421 2026-05-28

Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy

Case Comprehensive Cancer Center

Phase NA Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT07053462 2025-07-08

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Failure, Chronic, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡